What one share of Upstream Bio holds
We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
Upstream Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$2.89 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.52 |
| Cash and investments | $1.45 |
| Book value | $4.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.81 | −$12.95 | $0.05 | −$12.89 | — | −$41.15 |
| 2024 | $0.17 | −$5.58 | $0.04 | −$4.36 | — | — |
| 2025 | $0.05 | −$2.66 | $0.00 | −$2.48 | — | $6.26 |
Common questions about Upstream Bio
How much does one share of Upstream Bio earn?
Over the last 12 months, Upstream Bio lost $2.89 for each share on $0.06 of sales.
Does Upstream Bio pay a dividend?
Upstream Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Upstream Bio’s book value per share?
Upstream Bio’s book value is $4.95 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Upstream Bio have?
Each share of Upstream Bio has $1.45 of cash and investments, as of June 30, 2026.
What is Upstream Bio’s free cash flow per share?
−$2.52 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.